Validation of Peptest™ in Patients with Gastro-Esophageal Reflux Disease and Laryngopharyngeal Reflux Undergoing Impedance Testing.


Journal

Journal of gastrointestinal and liver diseases : JGLD
ISSN: 1842-1121
Titre abrégé: J Gastrointestin Liver Dis
Pays: Romania
ID NLM: 101272825

Informations de publication

Date de publication:
09 Dec 2019
Historique:
received: 06 08 2019
accepted: 06 11 2019
entrez: 12 12 2019
pubmed: 12 12 2019
medline: 17 6 2020
Statut: epublish

Résumé

Pepsin in the gastric refluxate is a marker for a prior reflux event and rapid detection might be achieved using the Peptest™, an in vitro diagnostic medical device. The aim of this study was to validate the use of Peptest™ to reliably diagnose reflux in patients with gastro-esophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR) disease diagnosed with multichannel intraluminal impedance/ pHmetry (MII-pH). 20 reflux patients were recruited of whom 10 had classical GERD and 10 had LPR. All patients underwent MII-pH and provided expectorated saliva samples when a MII-pH reflux event was observed, or reflux symptoms were experienced, and all were tested for the presence of pepsin using the Peptest™. Pepsin was detected in 31 out of 45 samples (68.9%). At least 1 positive pepsin result was seen in 16 patients (80%) and this was the same, irrespective of the GERD or LPR diagnosis. Peptest™ had a positive predictive value of 69% to detect MII-pH reflux events. Peptest™ is a good first-line diagnostic procedure to use in reflux sufferers to confirm the presence of reflux.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Pepsin in the gastric refluxate is a marker for a prior reflux event and rapid detection might be achieved using the Peptest™, an in vitro diagnostic medical device. The aim of this study was to validate the use of Peptest™ to reliably diagnose reflux in patients with gastro-esophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR) disease diagnosed with multichannel intraluminal impedance/ pHmetry (MII-pH).
METHODS METHODS
20 reflux patients were recruited of whom 10 had classical GERD and 10 had LPR. All patients underwent MII-pH and provided expectorated saliva samples when a MII-pH reflux event was observed, or reflux symptoms were experienced, and all were tested for the presence of pepsin using the Peptest™.
RESULTS RESULTS
Pepsin was detected in 31 out of 45 samples (68.9%). At least 1 positive pepsin result was seen in 16 patients (80%) and this was the same, irrespective of the GERD or LPR diagnosis. Peptest™ had a positive predictive value of 69% to detect MII-pH reflux events.
CONCLUSIONS CONCLUSIONS
Peptest™ is a good first-line diagnostic procedure to use in reflux sufferers to confirm the presence of reflux.

Identifiants

pubmed: 31826051
doi: 10.15403/jgld-335
doi:

Substances chimiques

Biomarkers 0
Pepsin A EC 3.4.23.1

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-387

Auteurs

Serhat Bor (S)

Section of Gastroenterology, Ege University School of Medicine, Ege Reflux Study Group, Izmir, Turkey. . serhat.bor@ege.edu.tr.

Doga Capanoglu (D)

Section of Gastroenterology, Ege University School of Medicine, Ege Reflux Study Group, Izmir, Turkey. dogacapan@gmail.com.

Rukiye Vardar (R)

Section of Gastroenterology, Ege University School of Medicine, Ege Reflux Study Group, Izmir, Turkey. rukiye.vardar@ege.edu.tr.

Andrew D Woodcock (AD)

RD Biomed Limited, Castle Hill Hospital, United Kingdom. andrew.woodcock@rdbiomed.com.

Jeanine Fisher (J)

RD Biomed Limited, Castle Hill Hospital, United Kingdom. jeanine.fisher@technostics.com.

Peter William Dettmar (PW)

RD Biomed Limited, Castle Hill Hospital, United Kingdom. peter.dettmar@rdbiomed.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH